Recent status of the antisense oligonucleotide approaches in oncology

Fundamental and Clinical Pharmacology

Volumn 10, Issue 2, 1996, Pages 97-115

  Ma, L ^a   Calvo, F ^a  

^a SAINT LOUIS HOSPITAL   (France)

Author keywords

antisense oligonucleotides; clinical trials; in vivo experiments; oncology

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CYTOSTATIC AGENT; GROWTH FACTOR; MAFOSFAMIDE; MESSENGER RNA; NUCLEAR PROTEIN; TRANSCRIPTION FACTOR;

ANIMAL MODEL; CANCER; CANCER THERAPY; CLINICAL TRIAL; DRUG RESEARCH; DRUG TARGETING; GENE EXPRESSION; HUMAN; HYBRIDIZATION; LEUKEMIA; NONHUMAN; ONCOGENE; ONCOLOGY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; VIRUS;

EID: 0029933947     PISSN: 07673981     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1472-8206.1996.tb00153.x     Document Type: Review

References (170)

1. Abubakr YA, Mohammad R, Maki A et al. Effectiveness of bcl-2 antisense oligodeoxynucleotides (AS-ODN) against human follicular small-cleaved cell lymphoma (FSCCL)-SCID mice xenograft model. Blood 1994;84(suppl 1):374a
2. Ackermann K, Fauss J, Pyerin W. Inhibition of cyclic AMP-triggered aromatase gene expression in human choriocarcinoma cells by antisense oligodeoxynucleotide. Cancer Res 1994;54:4940
3. Agrawal S, Tang JY. GEM 91-an antisense oligonucleotide phosphorothioate as a therapeutic agent for AIDS. Antisense Res Dev 1992;2:261
4. Alama A, Meazza R, Barbieri F, Biassoni R, Mazzei M, Nicolin A. Antiproliferative effect of DNA polymerase a antisense oligodeoxynucleotides on breast cancer cells. Exp Cell Res 1993;206:318
5. Augustyns K, Godard G, Hendrix C et al. Hybridization specificity, enzymatic activity and biological (Ha-ras) activity of oligonucleotides containing 2,4-dideoxy-β-erythro-hexopyranosyl nucleosides. Nucleic Acids Res 1993;21:4670
6. Azuma E, Hiratake S, Nishiguchi Y et al. In vivo treatment of multidrug-resistant murine leukemia with antisense MDR1 oligodeoxynucleotides. Blood 1994;84(suppl 1):43a
7. Barut B, Chauhan D, Uchiyama H, Anderson KC. Interleukin-6 functions as an intracellular growth factor in hairy cell leukemia in vitro. J Clin Invest 1993;92:2346
8. Bayever E, Iversen P. Oligonucleotides in the treatment of leukemia. Hematol Oncol 1994;12:9
9. Bayever E, Iversen P, Smith L, Spinolo J, Zon G. Systemic human antisense therapy begins. Antisense Res Dev 1992;2: 109
10. Bayever E, Bishop MR, Zon G, Spinolo J, Kessinger A. Human studies using antisense against p53 in AML. Proc Am Assoc Cancer Res 1993a;34:593
11. Bayever E, Iversen PL, Bishop MR et al. Systemic administration of a phosphorothioate oligonucleotide with a sequence complementary to p53 for acute myelogenous leukemia and myelodysplastic syndrome: initial results of a phase I trial. Antisense Res Dev 1993b;3:383
12. Behl C, Bogdahn U, Winkler J, Apfel R, Brysch W, Schlingensiepen KH. Autoinduction of platelet derived growth factor (PDGF) A-chain mRNA expression in a human malignant melanoma cell line and growth inhibitory effects of PDGF-A-chain mRNA-specific antisense molecules. Biochem Biophys Res Commun 1993a;193:744
13. Behl C, Winkler J, Bogdahn U, Meixensberger J, Schlingensiepen KH, Brysch W. Autocrine growth regulation in neuroectodermal tumors as detected with oligodeoxynucleotide antisense molecules. Neurosurgery 1993b;33:679
14. 2 enzyme activity by phophorothioate oligonucleotides. Nucleic Acids Res 1994;22:3202
15. ber-abl tyrosine kinase autophosphorylation by oligonucleotides of defined sequence and backbone structure. Nucleic Acids Res 1994;22:2150
16. Bergan R, Connell Y, Fahmy B, Neckers L. Electroporation enhances c-myc antisense oligodeoxynucleotide efficacy. Nucleic Acids Res 1993;21:3567
17. Bertram J, Killian M, Schlingensiepen KH, Kneba M. Reduction of erbB2 gene production in mamma carcinoma cell lines by erbB2 mRNA-specific and tyrosine kinase consensus phosphorothioate antisense oligonucleotides. Biochem Biophys Res Commun 1994;200:661
18. Bi S, Lanza F, Goldman JM. The abnormal p53 protein expressed in CML cell lines are non-functional. Leukemia 1993;7:1840
19. Bi S, Lanza F, Goldman JM. The involvement of "tumor suppressor" p53 in normal and chronic myelogenous leukemia hemopoiesis. Cancer Res 1994;54:582
20. Bishop MR, Bayever E, Iversen PL et al. Phase I trial of systemic administration of OL(1)p53 oligonucleotide in refractory acute myelogenous leukemia and advanced myelodysplastic syndrome. Blood 1993;82(suppl 1):443a
21. Bishop MR, Joshi SS, Jackson JD et al. Purging of peripheral blood progenitor cells with antisense oligonucleotide directed against bcr-abl for chronic myelogenous leukemia. Blood 1994;84(suppl 1):740a
22. Bold RJ, Warren RE, Ishizuka J, Cho-Chung YS, Townsend CM Jr, Thompson JC. Experimental gene therapy of human colon cancer. Surgery 1994;116:189
23. Bourjrad N, Hudson JR Jr, Papadopoulos V. Inhibition of hormone-stimulated steroidogenesis in cultured Leydig tumor cells by a cholesterol-linked phosphorothioate oligodeoxynucleotide antisense to diazepam-binding inhibitor. Proc Natl Acad Sci USA 1993;90:5728
24. Brennscheidt U, Riedel D, Kölch W et al. Raf-1 is a necessary component of the mitogenic response of the human megakaryoblastic leukemia cell line MO7 to human stem cell factor, granulocyte-macrophage colony-stimulating factor, interleukin 3, and interleukin 9. Cell Growth Differ 1994;5:367
25. Brown DA, Kang SH, Gryaznov SM et al. Effects of phosphorothioate modification of oligonucleotides on specific protein binding. J Biol Chem 1994;269:26801
26. Bruno E, Murray LJ, Wang HM, Fu J et al. Partial inhibition of the megakaryocyte-colony stimulating activity of human interleukin-3 by antisense oligonucleotides to the protooncogene c-mpl. Blood 1994;84(suppl 1):328a
27. Calabretta B, Skorski T, Szczylik C, Zon G. Prospects for gene-directed therapy with antisense oligonucleotides. Cancer Treat Rev 1993;19:169
28. Campos L, Sabido O, Rouault JP, Guyotat D. Effects of bcl-2 antisense oligodeoxynucleotides on in vitro proliferation and survival of normal marrow progenitors and leukemic cells. Blood 1994;84:595
29. Carter G, Lemoine NR. Antisense technology for cancer therapy: does it make sense? Br J Cancer 1993;67:869
30. Cho-Chung YS, Clair T. The regulatory subunit of cAMP-dependent protein kinase as a target for chemotherapy of cancer and other cellular dysfunctional-related diseases. Pharmacol Ther 1993;60:265
31. Ciardiello F, Tortora G, Bianco C et al. Inhibition of CRIPTO expression and tumorigenicity in human colon cancer cells by antisense RNA and oligodeoxynucleotides. Oncogene 1994;9:291
32. Citro G, Szczylik C, Ginobbi P, Zupi G, Calabretta B. Inhibition of leukaemia cell proliferation by folic acid-polylysine-mediated introduction of c-myb antisense oligodeoxynucleotides into HL-60 cells. Br J Cancer 1994;69:463
33. Clark RE, Giles RV, Green JA, Tidd DM. Optimisation of antisense oligodeoxynucleotide structure for targeting chronic myeloid leukemia (CML). Blood 1994;84(suppl 1):156a
34. Colomer R, Lupu R, Bacus SS, Gelmann EP. erbB-2 antisense oligonucleotides inhibit the proliferation of breast carcinoma cells with erbB-2 oncogene amplification. Br J Cancer 1994;70:819
35. Cotter FE, Johnson P, Hall P et al. Antisense oligonucleotides suppress B-cell lymphoma growth in a SCID-hu mouse model. Oncogene 1994;9:3049
36. Croxtall JD, Flower RJ. Antisense oligonucleotides to human lipocortin-1 inhibit glucocorticoid-induced inhibition of A549 cell growth and eicosanoid release. Biochem Pharmacol 1994;48:1729
37. De Fabritiis P, Amadori S, Calabretta B, Mandelli F. Elimination of clonogenic Philadelphia-positive cells using bcr-abl antisense oligodeoxynucleotides. Bone Marrow Transplant 1993;12:261
38. De Lord C, Clutterbuck RD, Powles RL, Min T, Titley JC, Millar JL. Human Philadelphia chromosome positive chronic myeloid leukemia: a potential model for antisense therapy. Exp Hematol 1993;21:826
39. Dean NM, McKay R. Inhibition of protein kinase C-α expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotides. Proc Natl Acad Sci USA 1994;91:11762
40. Dean NM, McKay R, Condon TP, Bennett CF. Inhibition of protein kinase C-α expression in human A549 cells by antisense oligonucleotides inhibits induction of intercellular adhesion molecule 1 (ICAM-1) mRNA by phorbol esters. J Biol Chem 1994;269:16416
41. Delgado MD, Hallier M, Meneceur P, Tavitian A, Moreau-Gachelin F. Inhibition of Friend cells proliferation by spi-1 antisense oligodeoxynucleotides. Oncogene 1994; 9:1723
42. Deng G, Eh Z, Xu Y, Lu Y. Activation of oncogene c-Ha-ras in gastric cancer of Chinese patients. Semin Surg Oncol 1994; 10:83
43. Dewanjee MK, Ghatouripour AK, Kapadvanjwala M et al. Noninvasive imaging of c-myc oncogene messenger RNA with indium-111-antisense probes in a mammary tumor-bearing mouse model. J Nucl Med 1994a;35:1054
44. 111In-labeled antisense oligodeoxynucleotide probes by high-pressure liquid chromatography. Biotechniques 1994b; 16:844
45. Ensoli B, Markham P, Kao V et al. Block of AIDS-Kaposi's sarcoma (KS) cell growth, angiogenesis, and lesion formation in nude mice by antisense oligonucleotide targeting basic fibroblast growth factor. J Clin Invest 1994;94:1736
46. Ferrari S, Manfredini R, Tagliafica E et al. Antiapoptotic effect of c-fes protooncogene during granulocytic differentiation. Leukemia 1994;8(suppl 1):S91
47. Fischer G, Kent SC, Joseph L, Green DR, Scott DW. Lymphoma models for B cell activation and tolerance. X. Anti-μ-mediated growth arrest and apoptosis of murine B cell lymphomas is prevented by the stabilization of myc. J Exp Med 1994;179:221
48. Fonagy A, Swiderski C, Ostrovsky AM, Bolton WE, Freeman JW. Effect of nucleolar p120 expression level on the proliferation capacity of breast cancer cells. Cancer Res 1994; 54:1859
49. Fournier S, Rubio M, Delespesse G, Sarfati M. Role for low-affinity receptor for IgE (CD23) in normal and leukemic B-cell proliferation. Blood 1994;84:1881
50. Gamard CJ, Blobe GC, Hannun YA, Obeid LM. Specific role for protein kinase C β in cell differentiation. Cell Growth Differ 1994;5:405
51. Gee JE, Yen RL, Hung MC, Hogan ME. Triplex formation at the rat neu oncogene promotor. Gene 1994;149:109
52. Gewirtz AM. Potential therapeutic applications of antisense oligodeoxynucleotides in the treatment of chronic myelogenous leukemia. Leuk Lymphoma 1993a,11(suppl 1):131
53. Gewirtz AM. Therapeutic applications of antisense DNA in the treatment of human leukemia. Proc Am Assoc Cancer Res 1993b;34:595
54. Gottikh M, Baud-Demattei MV, Lescot E et al. In vitro inhibition of the pim-1 protooncogene by chimeric oligodeoxyribonucleotides composed of α- and β-anomeric fragments. Gene 1994;149:5
55. Gray GD, Hernandez OM, Hebel D, Root M, Pow-Sang JM, Wickstrom E. Antisense DNA inhibition of tumor growth induced by c-Ha-ras oncogene in nude mice. Cancer Res 1993;53:577
56. Guimaraes JETE, Szczylik C, Koziolkiewicz M, Moreira I, Ramos JP. An antisense oligonucleotide to the transferrin receptor inhibits proliferation of leukemic cells in vitro. Blood 1994;84(suppl 1):607a
57. Guvakova M, Yakubov LA, Vlodavsky I, Tonkinson JL, Stein CA. Phosphorothioate oligodeoxynucleotides bind to basic fibroblast growth factor, inhibit its binding to cell surface receptors, and remove it from low affinity binding sites on extracellular matrix. J Biol Chem 1995;270:2620
58. Higgins KA, Perez JR, Coleman TA et al. Antisense inhibition of the p65 subunit of NF-κB blocks tumorigenicity and causes tumor regression. Proc Natl Acad Sci USA 1993;90: 9901
59. Hijiya N, Zhang J, Ratajczak MZ et al. Biologic and therapeutic significance of MYB expression in human melanoma. Proc Natl Acad Sci USA 1994;91:4499
60. Huber J, Dittrich F, Phelan P. Characterization of high-affinity and low-affinity receptors for ciliary neurotrophic factor. Eur J Biochem 1993;218:1031
61. Jachimczak P, Bogdahn U, Schneider J et al. The effect of transforming growth factor-β2-specific phosphorothioate-anti-sense oligodeoxynucleotides in reversing cellular immunosuppression in malignant glioma. J Neurosurg 1993;78:944
62. Jänicke RU, Lee FHH, Porter AG. Nuclear c-myc plays an important role in the cytotoxicity of tumor necrosis factor alpha in tumor cells. Mol Cell Biol 1994;14:5661
63. 1 phase. Scand J Immunol 1994;39:499
64. Kay HD, Tarantolo S, Smith LJ. Antisense oligonucleotides inhibit expression of human multidrug-resistance (MDR1) gene dramatically increase in vitro chemosensitivity of human multiple myeloma cells. Blood 1994;84(suppl 1):39a
65. Keith FJ, Bradbury DA, Zhu YM, Russell NH. Inhibition of bcl-2 with antisense oligonucleotides induces apoptosis and increases the sensitivity of AML blasts to cytosine arabinoside. Blood 1994;84(suppl 1):142a
66. cdc2 and cyclin-dependent kinase-2 in T lymphocytes. J Immunol 1994;152:4328
67. Kirland MA, O'Brien SG, McDonald C, Davidson RJ, Cross NC, Goldman JM. BCR-ABL antisense purging in chronic myeloid leukemia. Lancet 1993;342:614
68. Kitada S, Miyashita T, Tanaka S, Reed JC. Investigations of antisense oligonucleotides targeted against bcl-2 RNAs. Antisense Res Dev 1993;3:157
69. Kizaki M, Sakashita A, Karmakar A, Lin CW, Koeffler HP. Regulation of manganeses superoxide dismutase and other antioxidant genes in normal and leukemic hematopoietic cells and their relationship to cytotoxicity by tumor necrosis factor. Blood 1993;82:1142
70. Kleuss C, Scherübl H, Hescheler J, Schultz G, Wittig B. Selectivity in signal transduction determined by γ subunits of heterotrimeric G proteins. Science 1993;259:832
71. Kobayashi S, Teramura M, Sugawara I, Oshimi K, Mizoguchi H. Interleukin-11 acts as an autocrine growth factor for human megakaryoblastic cell lines. Blood 1993;81:889
72. Kondo S, Yin D, Takeuchi J et al. Tumor necrosis factor-α induces an increase in susceptibility of human glioblastoma U87-MG cells to natural killer cell-mediated lysis. Br J Cancer 1994;69:627
73. Kouhara H, Koga M, Kasayama S, Tanaka A, Kishimoto T, Sato B. Transforming activity of a newly cloned androgen-induced growth factor. Oncogene 1994;9:455
74. Krieg AM, Yi AK, Matson S et al. CpG motifs in bacterial DNA triger direct B-cell activation. Nature 1995;374:546
75. Kuijpers WHA, Bos E, Kaspersen FM, Veeneman GH, van Boeckel CAA. Specific recognition of antisense-oligonucleotide conjugates by radiolabeled antisense nucleotides: a novel approach for two-step radioimmunotherapy of cancer. Bioconjug Chem 1994;4:94
76. Kuramoto E, Yano O, Kimura Y et al. Oligonucleotide sequences required for natural killer cell activation. Jpn J Cancer Res 1992;83:1128
77. Lewalle P, Martiat P. Inhibition of P210 expression in chronic myeloid leukemia: oligonucleotides and/or transduced antisense sequences. Leuk Lymphoma 1993;11(suppl 1):139
78. Lisziewicz J, Sun D, Metelev V, Zamecnik P, Callo RC, Agrawal S. Long-term treatment of human immunodeficiency virus-infected cells with antisense oligonucleotide phosphorothioates. Proc Natl Acad Sci USA 1993;90:3860
79. Lisziewicz J, Sun D, Weichold FF et al. Antisense oligodeoxynucleotide phosphorothioate complementary to gag mRNA blocks replication of human immunodeficiency virus type I in human peripheral blood cells. Proc Natl Acad Sci USA 1994;91:7942
80. Louie SW, Ramirez LM, Krieg AM, Maliszewski CR, Bishop GA. Endogenous secretion of IL-4 maintains growth and Thy-1 expression of a transformed B cell clone. J Immunol 1993;150:399
81. Lu C, Kerbel RS. Interleukin-6 undergoes transition from paracrine growth inhibitor to autocrine stimulator during human melanoma progression. J Cell Biol 1993;120:1281
82. Luger SM, Ratajczak MZ, Stadtmauer EA et al. Autografting for chronic myelogenous leukemia (CML) with c-myb antisense oligodeoxynucleotide purged bone marrow. Blood 1994;84(suppl 1):126a
83. Luo D, Chen H, Jimbow K. Cotransfection of genes encoding human tyrosinase and tyrosinase-related protein-1 prevents melanocyte death and enhances melanin pigmentation and gene expression of lamp-1. Exp Cell Res 1994;213:231
84. Magrath IT. Prospects for the therapeutic use of antisense oligonucleotides in malignant lymphomas. Ann Oncol 1994; 5(suppl 1):S67
85. Mahdi T, Alcalay D, Brizard A, Kitzis A, Guihot F, Tanzer J. In vitro treatment with p53 and/or RB antisense (AS) oligodeoxynucleotides in association with growth factors (GF) induces proliferation of normal peripheral blood stem cells. Blood 1994a;84(suppl 1):21a
86. Mahdi T, Alcalay D, Cognard C, Brizard A, Kitzis A, Tanzer J. Combined bcr/abl abrogation by antisense (AS) oligonucleotides and transfection by the wild type (wt) P53 gene induce apoptosis in K562 cells. Blood 1994b;84(suppl 1):138a
87. Mahon FX, Belloc F, Reiffers J. Antisense oligomers in chronic myeloid leukemia. Lancet 1993;341:566
88. 2 in chronic myeloid leukemia. Blood 1994;84(suppl 1):633a
89. Maran A, Maitra RK, Kumar A et al. Blockage of NF-κB signaling by selective ablation of an mRNA target by 2-5A antisense chimeras. Science 1994;265:789
90. McGahon A, Bissonnette R, Schmitt M, Cotter KM, Green DR, Cotter TG. bcr-abl maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. Blood 1994; 83:1179
91. McIntyre K, Lombardo-Gillooly K, Perez J et al. A sense phosphorothioate oligonucleotide directed to the initiation codon of transcription factor NF-kappaB p65 causes sequence-specific immune stimulation. Antisense Res Dev 1993;3:309
92. Merzak A, Koocheckpour S, Pilkington GJ. CD44 mediates human glioma cell adhesion and invasion in vitro. Cancer Res 1994;54:3988
93. Methia N, Louache F, Vainchenker W, Wendung F. Oligodeoxynucleotides antisense to the proto-oncogene c-mpl specifically inhibit in vitro megakaryocytopoiesis. Blood 1993;82:1395
94. Miele ME, Bennett CF, Miller BE, Welch DR. Enhanced metastatic ability of TNF-α-treated malignant melanoma cells is reduced by intercellular adhesion molecule-1 (ICAM-1, CD54) antisense oligonucleotides. Exp Cell Res 1994;214:231
95. Mizutani T, Hayashi M, Maeda A, Sasaki N, Yamashita T, Kasai N, Namioka S. Inhibition of mouse hepatitis virus multiplication by antisense oligonucleotide, antisense RNA, sense RNA and ribozyme. Adv Exp Med Biol 1993;342:129
96. Mizutani Y, Fukumoto M, Bonavida B, Yoshida O. Enhancement of sensitivity of urinary bladder tumor cells to cisplatin by c-myc antisense oligonucleotide. Cancer 1994;74: 2546
97. Monia BP, Lesnik EA, Gonzalez C et al. Evaluation of 2′-modified oligonucleotides containing 2′-deoxy gaps as antisense inhibitors of gene expression. J Biol Chem 1993;268:14514
98. Morrison RS, Giordano S, Yamaguchi F, Hendrickson S, Berger MS. Basic fibroblast growth factor expression is required for clonogenic growth of human glioma cells. J Neurosci Res 1993;34:502
99. Nagel KM, Pharm BS, Holstad SG, Pharm D, Isenberg KE. Oligonucleotide pharmacotherapy: an antigene strategy. Pharmacotherapy 1993;13:177
100. Nakashima H, Shoji Y, Kim SG et al. Anti-human immunodeficiency virus type 1 activity of phosphorothioate analogs of oligodeoxynucleotides: penetration and localization of oligodeoxynucleotides in HIV-1-infected MOLT-4 cells. Nucleic Acids Res. 1994;22:5004
101. Nesterova M, Cho-Chung YS. A single-injection protein kinase A-directed antisense treatment to inhibit tumor growth. Nature Med 1995;1:528
102. Nguyen HQ, Hoffman-Liebermann B, Liebermann DA. The zinc finger transcription factor Egr-1 is essential for and restricts differentiation along the macrophage lineage. Cell 1993;72:197
103. Nitta T, Sato K. Specific inhibition of c-sis protein synthesis and cell proliferation with antisense oligodeoxynucleotides in human glioma cells. Neurosurgery 1994;34:309
104. Noonberg SB, Scott GK, Garovoy MR, Benz CC, Hunt CA. In vivo generation of highly abundant sequence-specific oligonucleotides for antisense and triplex gene regulation. Nucleic Acids Res 1994;22:2830
105. Normanno N, Selvam MP, Qi CF et al. Amphiregulin as an autocrine growth factor for c-Ha-ras and c-erbB-2-transformed human mammary epithelial cells. Proc Natl Acad Sci USA 1994;91:2790
106. O'Brien SG, Kirkland MA, Goldman JM. Antisense therapy for malignant disease. Eur J Cancer 1994;30A:1160
107. Offensperger WB, Offensperger S, Walter E, Teubner K, Igloi G, Blum HE, Gerok W. In vivo inhibition of duck hepatitis B virus replication and gene expression by phosphorothioate modified antisense oligodeoxynucleotides. EMBO J 1993;12:1257
108. Pai SR, Bird RC. c-fos expression is required during all phases of the cell cycle during exponential cell proliferation. Anti-cancer Res 1994;14:985
109. Patinkin D, Lev-Lehman E, Ginzberg D, Zakut H, Eckstein F, Soreq H. Antisense acetylcholinesterase oligonucleotide promotes stem cell expansion and suppresses hematopoietic apoptosis. Blood 1994;84(suppl 1):574a
110. Perez JR, Higgins-Sochaski KA, Maltese JY, Narayanan R. Regulation of adhesion and growth of fibrosarcoma cells by NF-κB relA involves transforming growth factor β. Mol Cell Biol 1994a;14:5326
111. Perez JR, Li YL, Stein CA, Majumder S, van Oorschot A, Narayanan R. Sequence-independent induction of Sp 1 transcription factor activity by phosphorothioate oligonucleotides. Proc Natl Acad Sci USA 1994b;91:5957
112. Perlaky L, Saijo Y, Busch RK et al. Growth inhibition of human tumor cell lines by antisense oligonucleotides designed to inhibit p120 expression. Anticancer Drug Des 1993a;8:3
113. Perlaky L, Smetana K, Busch RK, Saijo Y, Busch H. Nucleolar and nuclear aberrations in human lox tumor cells following treatment with p 120 antisense oligonucleotide ISIS-3466. Cancer Lett 1993b;74:125
114. Persaud SJ, Jones PM. Antisense oligonucleotide inhibition of gene expression: application to endocrine systems. J Mol Endocrinol 1994;12:127
115. Pierga JY, Magdelenat H. Applications of antisense oligonucleotides in oncology. Cell Mol Biol 1994;40:237
116. Pietrzkowski Z, Mulholland G, Gomella L, Jameson BA, Wernicke D, Baserga R. Inhibition of growth of prostatic cancer cell lines by peptide analogues of insulin-like growth factor 1. Cancer Res 1993;53:1102
117. Pocock C, Al Mahdi N, Hall P, Morgan G, Cotter F. In vivo suppression of B-cell lymphoma with bcl-2 antisense oligonucleotides. Blood 1993;82(suppl 1):200a
118. Ramanathan M, Lantz M, MacGregor RD, Garovoy MR Hunt CA. Characterization of the oligonucleotide-mediated inhibition of interferon-γ-induced major histocompatibility complex class I and intercellular adhesion molecule-1. J Biol Chem 1994;269:24564
119. Reddy SV, Takahashi S, Dallas M, Williams RE, Neckers L, Roodman GD. Interleukin-6 antisense deoxyoligonucleotides inhibit bone resorption by giant cells from human giant cell tumors of bone. J Bone Miner Res 1994;9:753
120. Redmond A, Moran E, Clynes M. Multiple drug resistance in the human ovarian carcinoma cell line OAW42-A. Eur J Cancer 1993;29A:1078
121. Reinis M, Reinisova M, Korec E, Hlozanek I. Inhibition of hepatitis B virus surface gene expression by antisense oligodeoxynucleotides in a human hepatoma cell line. Folia Biol 1992;39:262
122. Resnicoff M, Ambrose D, Coppola D, Rubin R. Insulin-like growth factor-1 and its receptor mediate the autocrine proliferation of human ovarian carcinoma cell lines. Lab Invest 1993;69:756
123. Resnicoff M, Sell C, Rubini M et al. Rat glioblastoma cells expressing an antisense to the insulin-like growth factor-1 (IGF-1) receptor are nontumorigenic and induce regression of wild-type tumors. Cancer Res 1994;54:2218
124. Roger SY, Bradbury D, Kozlowski R, Russell NH. Evidence for internal autocrine regulation of growth in acute myeloblastic leukemia cells. Exp Hematol 1994;22:593
125. Rosolen A, Kyle E, Chavany C, Bergan R, Kalman ET, Crouch R, Neckers L. Effect of over-expression of bacterial ribonuclease H on the utility of antisense MYC oligodeoxynucleotides in the monocytic leukemia cell line U937. Biochemistry 1993;75:79
126. Rosti V, Bergamaschi G, Lucotti C, Danova M, Locatelli F, Rovati A, Cazzola M. Oligodeoxynucleotides antisense to c-abl specifically inhibit entry into S phase of CD34-positive hematopoietic cells and their differentiation to granulocyte-macrophage progenitors. Blood 1994;84 (suppl 1):125a
127. Ryte A, Morelli S, Mazzei M et al. Oligonucleotide degradation contributes to resistance to antisense compounds. Anticancer Drugs 1993;4:197
128. Saijo Y, Perlaky L, Valdez BC, Wang H, Henning D, Busch H. Cellular pharmacology of p120 antisense oligodeoxynucleotide phosphorothioate ISIS 3466. Oncol Res 1993;5:283
129. Sakakura C, Hagiwara A, Tsujimoto H et al. Inhibition of gastric cancer cell proliferation by antisense oligonucleotides targeting the messenger RNA encoding proliferating cell nuclear antigen. Br J Cancer 1994;70:1060
130. Samuel SK, Hurta RAR, Spearman MA, Wright JA, Turley EA, Greenberg AH. TGF-β1 stimulation of cell locomotion utilizes the hyaluronan receptor RHAMM and hyaluronan. J Cell Biol 1993;123:749
131. Sasaki K, Sak O, Aisen P. Antisense suppression of transferrin receptor gene expression in a human hepatoma cell (HuH-7) line. Am J Hematol 1993;42:74
132. Schadendorf D, Möller A, Algermissen B, Worm M, Sticherling M, Czarnetzki BM. IL-8 produced by human malignant melanoma cells in vitro is an essential autocrine growth factor. J immunol 1993;151:2667
133. Scheuermann RH, Racila E, Tucker T et al. Lyn tyrosine kinase signals cell cycle arrest but not apoptosis in B-lineage lymphoma cells. Proc Natl Acad Sci USA 1994;91:4048
134. Schlüter C, Duchrow M, Wohlenberg C et al. The cell proliferation-associated antigen of antibody Ki-67: a very large, ubiquitous nuclear protein with numerous repeated elements, representing a new kind of cell cycle-maintaining proteins. J Cell Biol 1993;123:513
135. Schwab G, Chavany C, Duroux I et al. Antisense oligonucleotides adsorbed to polyalkylcyanoacrylate nanoparticles specifically inhibit mutated Ha-ras-medialed cell proliferation and tumorigenicity in nude mice. Proc Natl Acad Sci USA 1994;91:10460
136. Shea TB, Beermann ML, Fischer I. Transient requirement for vimentin in neuritogenesis: intracellular delivery of antivimentin antibodies and antisense oligonucleotides inhibit neurite initiation but not elongation of existing neurites in neuroblastoma. J Neurosci Res 1993;36:66
137. Skorski T, Kanakaraj P, Nieborowska-Skorska M et al. p120 GAP requirement in normal and malignant human hematopoiesis. J Exp Med 1993a;178:1923
138. Skorski T, Nieborowska-Skorska M, Barletta C et al. Highly efficient elimination of Philadelphia leukemic cells by exposure to bcr-abl antisense oligodeoxynucleotides combined with mafosfamide. J Clin Invest 1993b;92:194
139. bcr/abl: implication for ras-dependent Philadelphia chromosome positive cell growth. J Exp Med 1994a;179:1855
140. Skorski T, Nieborowska-Skorska M, Campbell K et al. Human leukemia treatment in SCID mice by antisense oligodeoxynucleotides targeting cooperating oncogenes. Blood 1994b;84(suppl 1):514a
141. 1 leukemia cell growth in mice by bcr-abl antisense oligodeoxynucleotide. Proc Natl Acad Sci USA 1994c;91:4504
142. Smetsers TFCM, Skorski T, van de Locht LTF et al. Antisense bcr-abl oligonucleotides induce apoptosis in the Philadelphia chromosome-positive cell line BV173. Leukemia 1994;8:129
143. Sokoloski JA, Sartorelli AC, Rosen CA, Narayanan R. Antisense oligonucleotides to the p65 subunit of NF-κB block CD11b expression and alter adhesion properties of differentiated HL-60 granulocytes. Blood 1993;82:626
144. Sott C, Dorner B, Karawajew L, Herrmann F, Brach MA. Transforming growth factor-β relieves stem cell factor-induced proliferation of myelogenous leukemia cells through inhibition of binding of the transcription factor NF-jun. Blood 1994;84:1950
145. Sparatore B, Patrone M, Passalacqua M et al. Characterization of the biological role of murine erythroleukemia cells "differentiation enhancing factor" using antisense oligodeoxynucleotides. Biochem Biophys Res Commun 1993; 193:941
146. Spearman M, Taylor WR, Greenberg AH, Wrignt JA. Antisense oligodeoxynucleotide inhibition of TGF-β1 gene expression and alteration in the growth and mignant properties of mouse bifrosarcoma cells. Gene 1994;149:25
147. Steele C, Cowsert LM, Shillitoe EJ. Effects of human papillomavirus type 18-specific antisense oligonucleotides on the transformed phenotype of human carcinoma cell lines. Cancer Res 1993;53:2330
148. Stein CA, Cheng YC. Antisense oligonucleotides as therapeutic agents is the bullet really magical? Science 1993;261:1004
149. Stein CA, Krieg AM. Problems in interpretation of data derived from in vitro and in vivo use of antisense oligonucleotides. Antisense Res Dev 1994;4:67
150. Takeshita K, Bollekens JA, Hijiya N, Ratajczak M, Ruddle FH, Gewirtz AM. A homeobox gene of the antennapedia class is required for human adult erythropoiesis. Proc Natl Acad Sci USA 1993;90:3535
151. Takeuchi K, Sato N, Kasahara H et al. Perturbation of cell adhesion and microvilli formation by antisense oligonucleotides to ERM family members. J Cell Biol 1994;125:1371
152. Tang JY, Temsamani J, Agrawal S. Self-stabilized antisense oligodeoxynucleotide phosphorothioates: properties and anti-HIV activity. Nucleic Acids Res 1993;21:2729
153. Tari AM, Tucker SD, Deisseroth A, Lopez-Berestein G. Liposomal delivery of methylphosphonate antisense oligodeoxynucleotides in chronic myelogenous leukemia. Blood 1994;84:601
154. 2+ channels in IMR 32 human beuroblastoma cells. Biochem Biophys Res Commun 1994;201:180
155. Thierry AR, Rahman A, Dritschilo A. Overcoming multidrug resistance in human tumor cells using free and liposomally encapsulated antisense oligodeoxynucleotides. Biochem Biophys Res Commun 1993;190:952
156. Thomas M, Kosciolek B, Wang N, Rowley P. Capping of bcr-abl antisense oligonucleotides enhances antiproliferative activity against chronic myeloid leukemia cell lines. Leuk Res 1994;18:401
157. Thulasi R, Harbour DV, Thompson EB. Suppression of c-myc is a critical step in glucocorticoid-induced human leukemic cell lysis. J Biol Chem 1993;268:18306
158. Wagner RW. Gene inhibition using antisense oligonucleotides. Nature 1994;372:333
159. Watson JM, Berek JS, Martinez-Maza O. Growth inhibition of ovarian cancer cells induced by antisense IL-6 oligonucleotides. Gynecol Oncol 1993;49:8
160. Xu X, Thomas ML. Estrogen receptor-mediated stimulation of colon cancer cell growth in vitro. Mol Cell Endocrinol 1994;105:197
161. Yamamoto T, Yamamoto S, Kataoka T, Tokunaga T. Ability of oligonucleotides with certain palindromes to induce interferon production and augment natural killer cell activity is associated with their base length. Antisense Res Dev 1994;4:119
162. Yang Y, Yelavarthi KK, Chen HL, Pace JL, Terranova PF, Hunt JS. Molecular, biochemical, and functional characteristics of tumor necrosis factor-α produced by human placental cytotrophoblastic cells. J immunol 1993;150:5614
163. Yao XR, Scott DW. Antisense oligodeoxynucleotides to the blk tyrosine kinase prevent anti-μ-chain-mediated growth inhibition and apoptosis in a B-cell lymphoma. Proc Natl Acad Sci USA 1993;90:7946
164. Yokozaki H, Budillon A, Tortora G et al. An antisense oligodeoxynucleotide that depletes RIa subunit of cyclic AMP-dependent protein kinase induces growth inhibition in human cancer cells. Cancer Res 1993;53:868
165. Zelphati O, Imbach JL, Signoret N, Zon G, Rayner B, Leserman L. Antisense oligonucleotides in solution or encapsulated in immunoliposomes inhibit replication of HIV-1 by several different mechanisms. Nucleic Acids Res 1994a;22: 4307
166. Zelphati O, Wagner E, Leserman L. Synthesis and anti-HIV activity of thiocholesteryl-coupled phosphodiester antisense oligonucleotides incorporated into immunoliposomes. Anti-viral Res 1994b;25:13
167. Zhao QY, Waldschmidt T, Fisher E, Herrera CJ, Krieg AM. Stage-specific oligonucleotide uptake in murine bone marrow B-cell precursors. Blood 1994;84:3660
168. Zhao QY, Temsamani J, Iadarola PL, Jiang ZW, Agrawal S. Effect of different chemically modified oligodeoxynucleotides on immune stimulation. Biochem Pharmacol 1996; 51:173
169. Zhou JH, Pai BS, Reed MW et al. Discovery of short, 3′-cholesterol-modified DNA duplexes with unique antitumor cell activity. Cancer Res 1994;54:5783
170. Zhu YM, Bradbury DA, Ressell NH. Wild-type p53 is required for apoptosis induced by growth factor deprivation in factor-dependent leukemic cells. Br J Cancer 1994;69:468